UK’s Aspire Acquired By HIG
Aspire CEO Talks About Expanding Geographical Footprint
UK firm Aspire, known for producing niche generics and specialty products, has found new ownership after being acquired by investment firm HIG Capital. Talking exclusively to Generics Bulletin, Aspire founder and CEO Graham Fraser-Pye, now chairman of the company, said that HIG would help Aspire grow and support new initiatives such as mergers and acquisitions and international expansion.
You may also be interested in...
Adamis has announced receiving FDA approval for Zimhi, its high-dose naloxone hydrochloride for injection, indicated for the treatment of opioid overdose. The company has partnered with US WorldMeds to market Zimhi by the first quarter of 2022.
US-based Phlow and Fresenius Kabi have announced an alliance to supply essential medicines, including injectables, for public health emergencies and to Children’s Hospital Coalition, a project by Phlow. In an exclusive interview with Generics Bulletin, Phlow chief business officer Dan Hackman talks about the partnership, addressing US supply chain disruptions, domestic manufacturing and more.
The Biosimilars Forum, in partnership with the Pacific Research Institute, has released a report that shows state-by-state cost savings for the US if biosimilars were able to capture a market share of 75%. Meanwhile, the Association for Accessible Medicines has also released its complete 2021 US Generic And Biosimilar Medicines Savings Report, discouraging reducing incentives for patent challenges and early generic entry.